Alseres Pharmaceuticals, Inc. (ALSE)
- Previous Close
0.0100 - Open
0.0100 - Bid --
- Ask --
- Day's Range
0.0050 - 0.0050 - 52 Week Range
0.0050 - 0.0100 - Volume
66 - Avg. Volume
0 - Market Cap (intraday)
199,127 - Beta (5Y Monthly) 0.16
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson's disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.
www.alseres.comRecent News: ALSE
Performance Overview: ALSE
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALSE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALSE
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-163.94%
Return on Assets (ttm)
-247.06%
Return on Equity (ttm)
--
Revenue (ttm)
473.73k
Net Income Avi to Common (ttm)
-776.64k
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
186.95k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.43M
Research Analysis: ALSE
Company Insights: ALSE
ALSE does not have Company Insights